IGC Pharma (FRA:IGS1) FFO


FRA:IGS1 IGC Pharma Inc FRA:IGS1
30 GF Score
Price €0.24
GF Value €0.20
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is IGC Pharma FFO?

FFO (Funds from operations) only applies to REITs.

FRA:IGS1
30GF Score
IGC Pharma Inc FRA:IGS1
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is IGC Pharma (FRA:IGS1) Overvalued in 2026?

Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued. The current stock price of €0.24 is trading 19% above its estimated GF Value™ of €0.20. GuruFocus considers IGC Pharma to be Modestly Overvalued.

Key valuation signals for FRA:IGS1:

  • FFO:
  • GF Value™: €0.20 vs. price of €0.24 (19% above fair value)
  • GF Score™: 30/100 with 6 warning signs

No single metric tells the full story. See the FRA:IGS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IGC Pharma Business Description

Other Exchanges IGC:USA
Address 10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
30GF Score

Get the complete analysis for FRA:IGS1

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.24
Price
€0.20
GF Value